Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease.
The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2016 Feb 08 [Epub ahead of print]
J Cassinello, J Carballido Rodríguez, L Antón Aparicio
Medical Oncology Service, Guadalajara University Hospital, c/Donantes de Sangre s/n. , 19002, Guadalajara, Spain. Urology Service, Puerta de Hierro University Hospital, Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain. , Medical Oncology Service, CHU Hospital, As Xubias 84 10, 15006, La Coruña, Galicia, Spain.